NCT04705168View on ClinicalTrials.gov

Study of the Nevisense Device to Assess Atypical Skin Lesions

Active, not recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

January 8, 2026

Study Completion Date

January 8, 2026

Conditions
NevusMultiple NeviLarge Acquired NeviSkin Lesion
Interventions
DIAGNOSTIC_TEST

Nevisense electrical impedance spectroscopy

Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Consent only), Harrison

07920

Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER